Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Dowlati, A.
Gray, R.
Johnson, D. H.
Schiller, J. H.
Brahmer, J.
Sandler, A. B.
机构：
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Univ Wisconsin, Madison, WI 53706 USA
[5] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：370S / 370S
页数：1
相关论文
共 50 条
  • [31] Safety analysis of a phase II randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (CX) in patients (pis) with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Argiris, Athanassios
    Lee, Ju-Whei
    Leach, Joseph W.
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [33] S0536: Carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC), a SWOG phase II study
    Kim, Edward S.
    Herbst, Roy S.
    Moon, James
    Redman, Mary W.
    Dakhil, Shaker R.
    Hirsch, Fred R.
    Mack, Phil
    Franklin, Wilbur
    Kelly, Karen
    Gandara, David
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S455 - S455
  • [34] Multicentre Phase II Trial of Paclitaxel and Carboplatin with Concurrent Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
    Tell, Roger
    Sederholm, Christer
    Klintenberg, Claes
    Franksson, Lars
    Branden, Eva
    Hillerdal, Gunnar
    Lonn, Ulf
    Linden, Carl-Johan
    Ewers, Sven-Borje
    Lamberg, Kristina
    Mrazek, Eva
    Loden, Britta
    Sjogren, Anders
    Linne, Thomas
    Friesland, Signe
    Sirzen, Florin
    ANTICANCER RESEARCH, 2008, 28 (5B) : 2851 - 2857
  • [35] A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer
    Kelly, K
    Mikhaeel-Kamel, N
    Pan, ZX
    Murphy, J
    Prindiville, S
    Bunn, PA
    CLINICAL CANCER RESEARCH, 2000, 6 (09) : 3474 - 3479
  • [36] S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study
    Gandara, D.
    Kim, E. S.
    Herbst, R. S.
    Moon, J.
    Redman, M. W.
    Dakhil, S. R.
    Hirsch, F.
    Mack, P. C.
    Franklin, W.
    Kelly, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Paclitaxel and Carboplatin in combination with Gemcitabine (PCG): A phase I-II trial in non-small cell lung cancer (NSCLC)
    Favaretto, A
    Paccagnella, A
    Tumolo, S
    Barbieri, F
    Ceresoli, G
    Gulisano, M
    Oniga, F
    Bearz, A
    Fiorentino, MV
    ANNALS OF ONCOLOGY, 1998, 9 : 91 - 91
  • [38] Biweekly carboplatin and gemcitabine for untreated advanced non-small cell lung cancer (NSCLC). A multicenter phase II trial
    Domine, M
    Gomez, RG
    Firvida, J
    Delgado, J
    Estevez, L
    Docampo, LI
    Leon, A
    Pachon, V
    Casado, V
    Lobo, F
    LUNG CANCER, 2005, 49 : S242 - S242
  • [39] Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
    Semrad, Thomas John
    Redman, Mary Weber
    Herbst, Roy S.
    Kim, Edward S.
    Bazhenova, Lyudmila
    Masters, Gregory A.
    Oettel, Kurt R.
    Guaglianone, Perry
    Reynolds, Christopher M.
    Karnad, Anand B.
    Arnold, Susanne M.
    Varella-Garcia, Marileila
    Moon, James
    Mack, Philip C.
    Blanke, Charles David
    Hirsch, Fred R.
    Kelly, Karen
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Randomized phase II trial of weekly squalamine, carboplatin, and paclitaxel as first line therapy for advanced non-small cell lung cancer.
    Rose, V
    Schiller, J
    Wood, A
    Eskander, E
    Holroyd, K
    Desai, A
    Lee, JT
    Ahmed, M
    Kim, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 643S - 643S
12345